| claim |
grand-strategy |
Cross-domain evidence from pharmaceutical governance (1906-1962) and arms control (ICBL) independently confirms the same three-component mechanism |
likely |
FDA regulatory history (sulfanilamide 1937, thalidomide 1961), ICBL case from Session 2026-03-31 |
2026-04-01 |
| extractor |
sourcer |
|
|
| handle |
context |
| leo |
FDA regulatory history (sulfanilamide 1937, thalidomide 1961), ICBL case from Session 2026-03-31 |
|
|
|
| pharmaceutical governance advances required triggering events not incremental advocacy because kefauver three year blockage preceded thalidomide breakthrough |
| pharmaceutical governance advances required triggering events not incremental advocacy because kefauver three year blockage proves technical expertise insufficient |
| triggering event architecture requires three components infrastructure disaster champion as confirmed by pharmaceutical and arms control cases |
|
| pharmaceutical governance advances required triggering events not incremental advocacy because kefauver three year blockage preceded thalidomide breakthrough|supports|2026-04-19 |
| pharmaceutical governance advances required triggering events not incremental advocacy because kefauver three year blockage proves technical expertise insufficient|supports|2026-04-19 |
| triggering event architecture requires three components infrastructure disaster champion as confirmed by pharmaceutical and arms control cases|supports|2026-04-20 |
| Weapons stigmatization campaigns require triggering events with four properties: attribution clarity, visibility, emotional resonance, and victimhood asymmetry|related|2026-04-20 |
|
| Weapons stigmatization campaigns require triggering events with four properties: attribution clarity, visibility, emotional resonance, and victimhood asymmetry |
|